BETHESDA, Md., Jan. 7 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced that it will participate inthe 28th Annual J.P. Morgan Healthcare Conference, to be held January 11th – 14th in San Francisco. Christian Itin, Ph.D., Micromet's President and CEO, will present a 30 minute corporate
The presentation will be webcast live and may be accessed by visiting the Micromet website at www.micromet-inc.com. A replay of the webcast will be available for 90 days.
About Micromet, Inc.
Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including sanofi-aventis, Bayer Schering Pharma, Merck Serono, MedImmune and Nycomed. Additional information can be found at www.micromet-inc.com.
SOURCE Micromet, Inc.
Subscribe to our Free Newsletters!
This is a branch of telemedicine that delivers eye care via a digital medical equipment and ...
Neuroblastoma is a very rare type of childhood cancer that develops in immature nerve cells ...View All